Section 1.5: Timing for Initiating Arginine Vasopressin in Septic Shock

Septic shock is frequently characterized by profound vasodilation. Prompt fluid resuscitation and vasopressor therapy are critical to maintaining tissue perfusion pressure and improving outcomes. Norepinephrine (NE), the guideline-recommended first-line vasopressor, may exhibit a “ceiling effect,” where further dose escalation fails to improve blood pressure and instead increases the risk of arrhythmias and worsens tissue perfusion. In such scenarios, adjunctive exogenous arginine vasopressin (AVP) has emerged as a valuable strategy to optimize hemodynamics. A global survey indicates that AVP is the most frequently used adjunctive vasopressor with NE; however, the optimal timing for its initiation remains debated: should it be guided by time since shock onset or by NE dosage requirements? Recently, target trial emulation and reinforcement learning models have begun exploring individualized strategies for AVP initiation.

I. Importance of Initiation Timing

Early septic shock typically presents as a hyperdynamic state with high cardiac output and low systemic vascular resistance. During this phase, intense sympathetic activation leads to massive endogenous release of catecholamines and AVP to maintain hemodynamic stability. While exogenous NE is generally effective initially, high doses can precipitate arrhythmias, increase myocardial oxygen demand, and pose significant risks. As the inflammatory cascade progresses, endothelial injury and overproduction of vasodilatory mediators (e.g., nitric oxide, prostaglandins) progressively diminish vascular responsiveness to NE, leading to vasoplegia. Concurrently, adrenal medullary exhaustion and pituitary suppression reduce endogenous AVP secretion, further worsening hemodynamics. At this stage, simply increasing the NE dose yields diminishing returns while amplifying adverse effects. AVP, acting via a non-adrenergic pathway (primarily V₁ receptors), directly induces vasoconstriction and complements NE in maintaining blood pressure and organ perfusion. Crucially, initiating AVP before complete loss of vascular responsiveness may interrupt the vicious cycle of “vasoplegia → high-dose NE → organ injury.” Conversely, delaying AVP until vasoplegia is profound and multiorgan failure has set in often renders it ineffective. Thus, the timing of AVP initiation not only dictates its hemodynamic efficacy but also determines whether it can provide physiologically stable vascular tone while minimizing catecholamine-related toxicity.

II. Dose-Driven Initiation Strategy

Since the 2008 VASST trial, AVP’s role as an adjunct to NE has been extensively studied. VASST randomized patients requiring ≥5 μg/min of NE, finding no overall mortality difference but suggesting a survival benefit in the AVP group when NE requirements were lower (<15 μg/min), implying that earlier introduction at lower NE doses may be advantageous. The subsequent VANISH trial confirmed the safety of AVP as a first-line agent, though it did not demonstrate superiority in the primary endpoint (renal failure-free days). Recent retrospective analyses similarly indicate that adding AVP at NE doses <0.25 μg/(kg·min) is associated with reduced 28-day mortality. Sacha et al. further noted that for every 10 μg/min increase in the NE dose at AVP initiation, mortality risk rises, and patients with lower lactate levels are more likely to benefit. Nevertheless, a purely “dose-driven” approach is increasingly challenged. NE dosage primarily reflects disease severity rather than physiological readiness for adjunctive therapy. Relying solely on a NE threshold overlooks individual organ perfusion status and heterogeneity, potentially delaying intervention and missing the optimal therapeutic window. Conversely, reaching a NE threshold in a stabilizing patient may not warrant AVP initiation. Therefore, NE dose should not be the sole criterion for AVP initiation; earlier, physiologically guided intervention windows should be prioritized.

III. Time-Driven Initiation Strategy

Alternative strategies utilize ICU admission time as a benchmark. A 2024 multicenter retrospective study across 12 Australian ICUs divided NE+AVP-treated septic shock patients into early (<6 hours, n=1,850) and late (≥6 hours, n=897) initiation groups, finding that early AVP administration was independently associated with lower in-hospital mortality. Similar studies using 7-hour or 12-hour thresholds consistently demonstrate that earlier AVP initiation correlates with faster shock reversal, lower atrial fibrillation incidence, and reduced mortality, reinforcing an “early combination” paradigm.

In 2025, a target trial emulation (TTE) based on a multicenter database provided novel evidence. Analyzing 3,105 septic shock patients, the TTE compared early AVP initiation (within 6 hours of shock diagnosis) versus delayed or no AVP use. The early initiation group had an estimated 30-day ICU mortality of 18.45%, compared to 19.34% in the non-use group (RR = 0.95, 95% CI 0.93–0.98). Benefits were particularly pronounced when AVP was initiated at lower NE doses [<0.25 μg/(kg·min)]. The study also highlighted evolving clinical practice from 2015 to 2021: AVP utilization increased from 35.2% to 45.1%, while the equivalent NE dose at AVP initiation decreased by an average of 0.05 μg/(kg·min) annually, reflecting growing consensus on early intervention. The TTE design mitigates common observational biases, offers robust statistical power with >3,000 patients, and adjusts for multiple confounders, enhancing clinical relevance. However, despite closely mimicking RCTs, residual confounding and heterogeneity in real-world prescribing may limit reproducibility. Moreover, the primary endpoint was 30-day mortality; long-term outcomes (e.g., renal function) were not assessed, warranting further investigation.

Recently, artificial intelligence has increasingly been integrated into critical care. In 2025, Kalimouttou et al. published the OVISS study in JAMA, pioneering the use of a reinforcement learning (RL) model to identify the “optimal AVP initiation timepoint.” Incorporating 3,105 ICU patients and dynamic clinical variables (NE dose, lactate, MAP, SOFA score), the RL model simulated various treatment trajectories and their impact on 30-day ICU mortality. The RL-recommended initiation times were consistently earlier than current guideline thresholds and correlated with significantly reduced 28-day mortality, particularly in high-risk patients with elevated lactate, organ dysfunction, or poor response to initial vasopressor therapy. These findings suggest that traditional “dose-driven” or fixed-time models may delay the therapeutic window. AVP initiation should transition from a “fixed-dose threshold” to an “individualized, physiology-driven” approach. Translating the “early initiation” concept into actionable, patient-specific strategies remains a critical area for future research.

IV. Limitations and Future Directions

As understanding of septic shock heterogeneity deepens, vasopressor therapy is shifting from a “fixed-timing, fixed-dose” empirical model toward precision strategies emphasizing individual physiological states. The optimal AVP initiation time is likely dictated by hemodynamic profiles and pathophysiological context rather than NE dosage alone. In hyperdynamic septic shock (high cardiac output, low SVR), early AVP co-administration may rapidly stabilize hemodynamics and spare NE. Conversely, in hypodynamic shock or patients with significant myocardial depression, AVP may exacerbate cardiac dysfunction by increasing afterload; initiation should be cautious, prioritizing cardiac optimization and inotropic support when needed. However, phenotype-guided AVP timing currently lacks robust evidence.

Theoretically, biomarkers could objectify individualized decision-making, but current data are inconclusive. Circulating AVP levels do not reliably predict hemodynamic responsiveness to exogenous AVP. Similarly, copeptin (a stable AVP precursor derivative) fails to accurately reflect plasma AVP concentrations in septic shock, limiting its utility for guiding initiation. Notably, AVP may offer organ-protective effects in specific subgroups. In patients at risk for or with established acute kidney injury, early low-dose AVP may confer renal protection by reducing NE requirements and constricting efferent arterioles, thereby maintaining glomerular filtration pressure.

In summary, consensus on the optimal AVP initiation timing in septic shock remains elusive. Current evidence favors early initiation (within 6–12 hours) at low-to-moderate NE doses [<0.25 μg/(kg·min)] when hemodynamic response is inadequate, catecholamine toxicity is a concern, or high-risk phenotypes (e.g., hyperdynamic shock, AKI) are present. As sepsis heterogeneity is better characterized, AVP initiation will likely evolve from rigid time/dose thresholds into a dynamic, individualized decision-making process grounded in real-time physiology and risk stratification.
(Shi Rui, Song Wenliang, Guan Xiangdong; First Affiliated Hospital, Sun Yat-sen University)